Immunovant Inc (IMVT)

$38.58 +0.07 (0.18%)
Market Cap 7.98B
Revenue (ttm) 0.00
Net Income (ttm) -505.61M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 956,499
Avg Vol 2,057,386
Day's Range N/A - N/A
Shares Out 205.31M
Stochastic %K 88%
Beta 0.76
Analysts Strong Sell
Price Target $45.28

Company Profile

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovan...

Industry: Biotechnology
Sector: Healthcare
Phone: 917 410 3120
Address:
1000 Park Forty Plaza, Suite 210, Durham, United States
Quantumup
Quantumup Jun. 29 at 4:48 PM
William Blair reiterated Viridian at an Outperform and said, We came away from the call incrementally more confident in the company's commercial readiness and the long-term opportunity for Lumvoa. $AMGN $IMVT - ROIV RHHBY TRML ALMS Wedbush⬆️ $VRDN's PT and said, Remain Outperform rated on VRDN, new $43 target. Here's what else Wedbush had to say: https://x.com/Quantumup1/status/2071636565064057133?s=20
0 · Reply
Quantumup
Quantumup Jun. 29 at 12:49 PM
UBS reiterated $VRDN Buy-$50 and said, VRDN announced Lumvoa (previously named veligrotug) is now approved in both active and chronic TED as expected, based on positive data from both THRIVE-1 and THRIVE-2. $AMGN $IMVT - ROIV ALMS RHHBY TRML Here's what else UBS had to say: https://x.com/Quantumup1/status/2071576402843861239?s=20
0 · Reply
TradeWiseSignals
TradeWiseSignals Jun. 24 at 1:19 AM
$IMVT is an add in my portfolio. Let’s see what it does.
0 · Reply
NVDAMillionaire
NVDAMillionaire Jun. 5 at 6:34 PM
$IMVT Great piece that accurately captures IMVT's current position. So if you want to refresh your understanding of IMVT or learn about IMVT for the first time, this is essential reading. https://everyticker.com/quote/IMVT/analysis/immunovant-s-7-billion-bet-can-imvt-1402-s-best-in-class-profile-justify-a-pipeline-in-a-product-valuation-nasdaq-imvt
0 · Reply
anachartanalyst
anachartanalyst May. 26 at 2:01 PM
$IMVT https://anachart.com/wp-content/uploads/2026/05/1779804088_soc-img.jpg
0 · Reply
ShadowBanningIsBad
ShadowBanningIsBad May. 22 at 4:32 PM
$MS $DDOG $IMVT $NXPI $VLO Remember sell high buy low.
1 · Reply
Clev21
Clev21 May. 21 at 7:24 PM
$IMVT she’s consolidating right now. Big move coming after hours
0 · Reply
KenCowboys
KenCowboys May. 21 at 2:59 PM
$IMVT trimmed just a little yesterday at $34 but will def add some back if it drops further
0 · Reply
secondideas
secondideas May. 21 at 2:51 PM
$IMVT dilution offering
0 · Reply
Quantumup
Quantumup May. 21 at 2:25 PM
TD Cowen⬆️ $ROIV's PT to $41 and reiterated at Buy. $IMVT $ABUS TD Cowen said—IMVT-1402 Shines In D2T RA, Many More Catalysts On Deck IMVT-1402 toplined impressive Ph2b D2T RA data w/ACR20 of 73%, ACR50 of 55%, and ACR70 of 36%. Brepo in CS received FDA BTD, on track to initiate Ph3 in H2:26. Brepo DM launch in late Sept, with our KOL anticipating bolus at launch. Next catalysts: brepo Ph3 data in NIU & mosli Ph2b data in PH-ILD in H2:26. Commercial launch of IMVT-1402 in Graves' & D2T RA expected in '27/28. New PT $41 (+$3).
2 · Reply
Latest News on IMVT
Immunovant price target raised to $61 from $57 at Citi

2026-06-30T10:40:09.000Z - 9 hours ago

Immunovant price target raised to $61 from $57 at Citi

Immunovant price target raised to $47 from $35 at JPMorgan

2026-05-26T17:57:21.000Z - 5 weeks ago

Immunovant price target raised to $47 from $35 at JPMorgan

Immunovant price target raised to $62 from $44 at Guggenheim

2026-05-26T11:07:38.000Z - 5 weeks ago

Immunovant price target raised to $62 from $44 at Guggenheim

Immunovant price target raised to $30 from $23 at Truist

2026-05-22T14:20:05.000Z - 5 weeks ago

Immunovant price target raised to $30 from $23 at Truist

Immunovant price target raised to $43 from $32 at BofA

2026-05-21T11:27:33.000Z - 5 weeks ago

Immunovant price target raised to $43 from $32 at BofA

Immunovant price target raised to $40 from $35 at H.C. Wainwright

2026-05-21T10:06:45.000Z - 5 weeks ago

Immunovant price target raised to $40 from $35 at H.C. Wainwright

Immunovant rises 33.6%

2026-05-20T16:06:43.000Z - 5 weeks ago

Immunovant rises 33.6%

This Is Why Immunovant Stock (IMVT) Is Up Today

2026-05-20T15:38:53.000Z - 5 weeks ago

This Is Why Immunovant Stock (IMVT) Is Up Today

2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug

May 20, 2026, 11:38 AM EDT - 5 weeks ago

2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug

ROIV

Immunovant rises 25.9%

2026-05-20T14:00:42.000Z - 5 weeks ago

Immunovant rises 25.9%

Immunovant Earnings Call Transcript: Q4 2026

May 20, 2026, 8:00 AM EDT - 5 weeks ago

Immunovant Earnings Call Transcript: Q4 2026

Immunovant Earnings release: Q4 2026

May 20, 2026, 8:00 AM EDT - 5 weeks ago

Immunovant Earnings release: Q4 2026

Immunovant Annual report: Q4 2026

May 20, 2026, 8:00 AM EDT - 5 weeks ago

Immunovant Annual report: Q4 2026

Immunovant reports Q4 EPS (73c), consensus (63)

2026-05-20T11:12:51.000Z - 5 weeks ago

Immunovant reports Q4 EPS (73c), consensus (63)

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

May 20, 2026, 7:00 AM EDT - 5 weeks ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

Immunovant Slides: Corporate presentation

May 20, 2026, 7:00 AM EDT - 5 weeks ago

Immunovant Slides: Corporate presentation

Immunovant price target raised to $32 from $29 at Goldman Sachs

2026-04-15T11:07:41.000Z - 2 months ago

Immunovant price target raised to $32 from $29 at Goldman Sachs

Immunovant price target lowered to $50 from $52 at Leerink

2026-04-02T15:31:15.000Z - 3 months ago

Immunovant price target lowered to $50 from $52 at Leerink

Morning Movers: Immunovant sinks after batoclimab trials miss goal

2026-04-02T13:01:48.000Z - 3 months ago

Morning Movers: Immunovant sinks after batoclimab trials miss goal

ALK ANRO APA BP CCL COP CVX

Immunovant Transcript: Study result

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Immunovant Transcript: Study result

Immunovant Press release: Study result

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Immunovant Press release: Study result

Immunovant Slides: Study result

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Immunovant Slides: Study result

Immunovant reports batoclimab clinical studies missed primary endpoint

2026-04-02T09:11:25.000Z - 3 months ago

Immunovant reports batoclimab clinical studies missed primary endpoint

Immunovant's treatment for eye disease fails late-stage trial

Apr 2, 2026, 5:06 AM EDT - 3 months ago

Immunovant's treatment for eye disease fails late-stage trial

Bernstein initiates Immunovant with a Market Perform, $28 price target

2026-03-20T12:50:25.000Z - 3 months ago

Bernstein initiates Immunovant with a Market Perform, $28 price target

Immunovant initiated with a Market Perform at Bernstein

2026-03-19T20:22:48.000Z - 3 months ago

Immunovant initiated with a Market Perform at Bernstein

Immunovant price target raised to $23 from $22 at Truist

2026-02-09T12:25:15.000Z - 5 months ago

Immunovant price target raised to $23 from $22 at Truist

Immunovant price target raised to $44 from $41 at Guggenheim

2026-02-09T11:52:26.000Z - 5 months ago

Immunovant price target raised to $44 from $41 at Guggenheim

Immunovant Earnings Call Transcript: Q3 2026

Feb 6, 2026, 8:00 AM EST - 5 months ago

Immunovant Earnings Call Transcript: Q3 2026

Immunovant Quarterly report: Q3 2026

Feb 6, 2026, 8:00 AM EST - 5 months ago

Immunovant Quarterly report: Q3 2026

Immunovant Earnings release: Q3 2026

Feb 6, 2026, 8:00 AM EST - 5 months ago

Immunovant Earnings release: Q3 2026

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

Feb 6, 2026, 7:00 AM EST - 5 months ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

Immunovant Slides: Corporate presentation

Feb 6, 2026, 7:00 AM EST - 5 months ago

Immunovant Slides: Corporate presentation

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

Jan 23, 2026, 5:25 PM EST - 5 months ago

Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

Immunovant Announces Pricing of $550 Million Common Stock Financing

Dec 11, 2025, 1:29 AM EST - 7 months ago

Immunovant Announces Pricing of $550 Million Common Stock Financing

Immunovant Earnings Call Transcript: Q2 2026

Nov 10, 2025, 8:00 AM EST - 8 months ago

Immunovant Earnings Call Transcript: Q2 2026

Immunovant Quarterly report: Q2 2026

Nov 10, 2025, 8:00 AM EST - 8 months ago

Immunovant Quarterly report: Q2 2026

Immunovant Earnings release: Q2 2026

Nov 10, 2025, 8:00 AM EST - 8 months ago

Immunovant Earnings release: Q2 2026

Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

Nov 10, 2025, 7:00 AM EST - 8 months ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

Immunovant Slides: Corporate Presentation

Nov 9, 2025, 6:00 PM EST - 8 months ago

Immunovant Slides: Corporate Presentation

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

Oct 27, 2025, 4:10 PM EDT - 8 months ago

Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

ROIV

Immunovant Slides: Corporate Presentation

Sep 4, 2025, 7:00 AM EDT - 10 months ago

Immunovant Slides: Corporate Presentation

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

Sep 3, 2025, 12:57 PM EDT - 10 months ago

Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

Immunovant Slides: Study update presentation

Sep 3, 2025, 7:00 AM EDT - 10 months ago

Immunovant Slides: Study update presentation

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2025

Immunovant Quarterly report: Q1 2026

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Immunovant Quarterly report: Q1 2026

Immunovant Earnings release: Q1 2026

Aug 11, 2025, 7:00 AM EDT - 11 months ago

Immunovant Earnings release: Q1 2026

Immunovant Proxy statement: Proxy Filing

Jul 9, 2025, 8:00 AM EDT - 1 year ago

Immunovant Proxy statement: Proxy Filing

Immunovant Proxy statement: Proxy Filing

Jul 9, 2025, 8:00 AM EDT - 1 year ago

Immunovant Proxy statement: Proxy Filing

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025

May 29, 2025, 7:00 AM EDT - 1 year ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025

Immunovant Annual report: Q4 2025

May 29, 2025, 7:00 AM EDT - 1 year ago

Immunovant Annual report: Q4 2025

Immunovant Earnings release: Q4 2025

May 29, 2025, 7:00 AM EDT - 1 year ago

Immunovant Earnings release: Q4 2025

Immunovant Transcript: BofA Securities 2025 Healthcare Conference

May 14, 2025, 7:20 PM EDT - 1 year ago

Immunovant Transcript: BofA Securities 2025 Healthcare Conference

Immunovant Transcript: Investor Update

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Immunovant Transcript: Investor Update

Immunovant Press release: Investor Update

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Immunovant Press release: Investor Update

Immunovant Slides: Investor Update

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Immunovant Slides: Investor Update

Immunovant Transcript: Status Update

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Immunovant Transcript: Status Update

Immunovant Press release: Status Update

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Immunovant Press release: Status Update

Immunovant Slides: Status Update

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Immunovant Slides: Status Update

Immunovant's muscle disorder treatment meets main goal in late-stage trial

Mar 19, 2025, 7:59 AM EDT - 1 year ago

Immunovant's muscle disorder treatment meets main goal in late-stage trial

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Mar 19, 2025, 7:45 AM EDT - 1 year ago

Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Mar 18, 2025, 4:32 PM EDT - 1 year ago

Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

Feb 6, 2025, 6:30 AM EST - 1 year ago

Immunovant Reports Financial Results for the Quarter Ended December 31, 2024

Immunovant Quarterly report: Q3 2025

Feb 6, 2025, 6:00 AM EST - 1 year ago

Immunovant Quarterly report: Q3 2025

Immunovant Earnings release: Q3 2025

Feb 6, 2025, 6:00 AM EST - 1 year ago

Immunovant Earnings release: Q3 2025

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

Jan 24, 2025, 1:34 PM EST - 1 year ago

Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm

Immunovant Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 10:30 AM EST - 1 year ago

Immunovant Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Immunovant Slides: FY 2025

Jan 14, 2025, 10:30 AM EST - 1 year ago

Immunovant Slides: FY 2025

FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline with Promising Results and FDA Green Light for Pivotal Trial

Dec 11, 2024, 6:25 AM EST - 1 year ago

FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline with Promising Results and FDA Green Light for Pivotal Trial

Immunovant Earnings Call Transcript: Q2 2025

Nov 7, 2024, 8:00 AM EST - 1 year ago

Immunovant Earnings Call Transcript: Q2 2025

Immunovant Quarterly report: Q2 2025

Nov 7, 2024, 8:00 AM EST - 1 year ago

Immunovant Quarterly report: Q2 2025

Immunovant Earnings release: Q2 2025

Nov 7, 2024, 8:00 AM EST - 1 year ago

Immunovant Earnings release: Q2 2025

Immunovant Slides: Q2 2025

Nov 7, 2024, 8:00 AM EST - 1 year ago

Immunovant Slides: Q2 2025

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

Nov 7, 2024, 6:30 AM EST - 1 year ago

Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting

Immunovant Transcript: Status Update

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Immunovant Transcript: Status Update

Immunovant Press release: Status Update

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Immunovant Press release: Status Update

Immunovant Slides: Status Update

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Immunovant Slides: Status Update

Immunovant Provides Update on Graves' Disease Development Program

Sep 9, 2024, 3:55 AM EDT - 1 year ago

Immunovant Provides Update on Graves' Disease Development Program

Immunovant to Host Graves' Disease Program Update on September 9, 2024

Sep 5, 2024, 6:30 AM EDT - 1 year ago

Immunovant to Host Graves' Disease Program Update on September 9, 2024

Immunovant Quarterly report: Q1 2025

Aug 6, 2024, 4:00 PM EDT - 2 years ago

Immunovant Quarterly report: Q1 2025

Immunovant Earnings release: Q1 2025

Aug 6, 2024, 4:00 PM EDT - 2 years ago

Immunovant Earnings release: Q1 2025

Immunovant Proxy statement: Proxy Filing

Jun 26, 2024, 8:00 AM EDT - 2 years ago

Immunovant Proxy statement: Proxy Filing

Immunovant Proxy statement: Proxy Filing

Jun 26, 2024, 8:00 AM EDT - 2 years ago

Immunovant Proxy statement: Proxy Filing

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

May 29, 2024, 4:01 PM EDT - 2 years ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024

Immunovant Annual report: Q4 2024

May 29, 2024, 4:00 PM EDT - 2 years ago

Immunovant Annual report: Q4 2024

Immunovant Earnings release: Q4 2024

May 29, 2024, 4:00 PM EDT - 2 years ago

Immunovant Earnings release: Q4 2024

Immunovant Awarded U.S. Patent for IMVT-1402

Mar 12, 2024, 7:30 AM EDT - 2 years ago

Immunovant Awarded U.S. Patent for IMVT-1402

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023

Feb 12, 2024, 7:00 AM EST - 2 years ago

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023

Immunovant Quarterly report: Q3 2024

Feb 12, 2024, 7:00 AM EST - 2 years ago

Immunovant Quarterly report: Q3 2024

Immunovant Earnings release: Q3 2024

Feb 12, 2024, 7:00 AM EST - 2 years ago

Immunovant Earnings release: Q3 2024

Immunovant Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 9, 2024, 10:30 AM EST - 2 years ago

Immunovant Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Immunovant Slides: FY 2024

Jan 9, 2024, 10:30 AM EST - 2 years ago

Immunovant Slides: FY 2024

Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 8:00 AM EST - 2 years ago

Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease

Dec 20, 2023, 4:30 PM EST - 2 years ago

Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves' Disease

Best Small-Cap Stocks to Buy for 2024 and Beyond

Dec 14, 2023, 1:24 PM EST - 2 years ago

Best Small-Cap Stocks to Buy for 2024 and Beyond

ARVN ASO BOOT FLYW GH PRVA RCKT

Immunovant Transcript: Study Update

Nov 28, 2023, 8:00 AM EST - 2 years ago

Immunovant Transcript: Study Update

Immunovant Press release: Study Update

Nov 28, 2023, 8:00 AM EST - 2 years ago

Immunovant Press release: Study Update

Immunovant Slides: Study Update

Nov 28, 2023, 8:00 AM EST - 2 years ago

Immunovant Slides: Study Update

Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

Nov 28, 2023, 7:00 AM EST - 2 years ago

Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential

Immunovant to Present at Upcoming Investor Conferences

Nov 13, 2023, 8:00 AM EST - 2 years ago

Immunovant to Present at Upcoming Investor Conferences

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023

Nov 9, 2023, 7:00 AM EST - 2 years ago

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023

Immunovant Quarterly report: Q2 2024

Nov 9, 2023, 7:00 AM EST - 2 years ago

Immunovant Quarterly report: Q2 2024

Immunovant Earnings release: Q2 2024

Nov 9, 2023, 7:00 AM EST - 2 years ago

Immunovant Earnings release: Q2 2024

Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 2, 2023, 4:52 PM EDT - 2 years ago

Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters' Option to Purchase Additional Shares

Immunovant Announces Pricing of $450 Million Common Stock Financing

Sep 27, 2023, 11:41 PM EDT - 2 years ago

Immunovant Announces Pricing of $450 Million Common Stock Financing

Immunovant Announces Proposed Offering of $300 Million of Common Stock

Sep 26, 2023, 5:00 PM EDT - 2 years ago

Immunovant Announces Proposed Offering of $300 Million of Common Stock

Immunovant Shares Skyrocket After Trial of Its Autoimmune Drug Beats Expectations

Sep 26, 2023, 4:20 PM EDT - 2 years ago

Immunovant Shares Skyrocket After Trial of Its Autoimmune Drug Beats Expectations

Immunovant Transcript: Study Result

Sep 26, 2023, 8:00 AM EDT - 3 years ago

Immunovant Transcript: Study Result

Immunovant Press release: Study Result

Sep 26, 2023, 8:00 AM EDT - 3 years ago

Immunovant Press release: Study Result

Immunovant Slides: Study Result

Sep 26, 2023, 8:00 AM EDT - 3 years ago

Immunovant Slides: Study Result

Immunovant shares surge after antibody treatment succeeds in early-stage study

Sep 26, 2023, 7:57 AM EDT - 3 years ago

Immunovant shares surge after antibody treatment succeeds in early-stage study

Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Sep 26, 2023, 6:00 AM EDT - 3 years ago

Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023

Sep 25, 2023, 11:01 PM EDT - 3 years ago

Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023

Immunovant Quarterly report: Q1 2024

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Immunovant Quarterly report: Q1 2024

Immunovant Earnings release: Q1 2024

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Immunovant Earnings release: Q1 2024

Immunovant Proxy statement: Proxy Filing

Jun 26, 2023, 8:00 AM EDT - 3 years ago

Immunovant Proxy statement: Proxy Filing

Immunovant Proxy statement: Proxy Filing

Jun 26, 2023, 8:00 AM EDT - 3 years ago

Immunovant Proxy statement: Proxy Filing

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023

May 22, 2023, 7:00 AM EDT - 3 years ago

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023

Immunovant Annual report: Q4 2023

May 22, 2023, 7:00 AM EDT - 3 years ago

Immunovant Annual report: Q4 2023

Immunovant Earnings release: Q4 2023

May 22, 2023, 7:00 AM EDT - 3 years ago

Immunovant Earnings release: Q4 2023

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022

Feb 3, 2023, 7:00 AM EST - 3 years ago

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022

Immunovant Quarterly report: Q3 2023

Feb 3, 2023, 7:00 AM EST - 3 years ago

Immunovant Quarterly report: Q3 2023

Immunovant Earnings release: Q3 2023

Feb 3, 2023, 7:00 AM EST - 3 years ago

Immunovant Earnings release: Q3 2023

Immunovant Transcript: Fireside Chat

Dec 8, 2022, 10:00 AM EST - 3 years ago

Immunovant Transcript: Fireside Chat

Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th

Nov 7, 2022, 8:00 AM EST - 3 years ago

Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th

Immunovant Quarterly report: Q2 2023

Nov 4, 2022, 8:00 AM EDT - 3 years ago

Immunovant Quarterly report: Q2 2023

Immunovant Earnings release: Q2 2023

Nov 4, 2022, 8:00 AM EDT - 3 years ago

Immunovant Earnings release: Q2 2023

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022

Nov 4, 2022, 7:00 AM EDT - 3 years ago

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022

Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock

Oct 4, 2022, 8:45 AM EDT - 4 years ago

Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock

Immunovant Transcript: Investor Day 2022

Sep 28, 2022, 11:15 AM EDT - 4 years ago

Immunovant Transcript: Investor Day 2022

Immunovant Press release: FY 2022

Sep 28, 2022, 11:15 AM EDT - 4 years ago

Immunovant Press release: FY 2022

Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn

Sep 28, 2022, 10:45 AM EDT - 4 years ago

Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn

Immunovant to Present at Roivant Investor Day on September 28th

Sep 21, 2022, 8:00 AM EDT - 4 years ago

Immunovant to Present at Roivant Investor Day on September 28th

Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th

Sep 9, 2022, 8:00 AM EDT - 4 years ago

Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th

Quantumup
Quantumup Jun. 29 at 4:48 PM
William Blair reiterated Viridian at an Outperform and said, We came away from the call incrementally more confident in the company's commercial readiness and the long-term opportunity for Lumvoa. $AMGN $IMVT - ROIV RHHBY TRML ALMS Wedbush⬆️ $VRDN's PT and said, Remain Outperform rated on VRDN, new $43 target. Here's what else Wedbush had to say: https://x.com/Quantumup1/status/2071636565064057133?s=20
0 · Reply
Quantumup
Quantumup Jun. 29 at 12:49 PM
UBS reiterated $VRDN Buy-$50 and said, VRDN announced Lumvoa (previously named veligrotug) is now approved in both active and chronic TED as expected, based on positive data from both THRIVE-1 and THRIVE-2. $AMGN $IMVT - ROIV ALMS RHHBY TRML Here's what else UBS had to say: https://x.com/Quantumup1/status/2071576402843861239?s=20
0 · Reply
TradeWiseSignals
TradeWiseSignals Jun. 24 at 1:19 AM
$IMVT is an add in my portfolio. Let’s see what it does.
0 · Reply
NVDAMillionaire
NVDAMillionaire Jun. 5 at 6:34 PM
$IMVT Great piece that accurately captures IMVT's current position. So if you want to refresh your understanding of IMVT or learn about IMVT for the first time, this is essential reading. https://everyticker.com/quote/IMVT/analysis/immunovant-s-7-billion-bet-can-imvt-1402-s-best-in-class-profile-justify-a-pipeline-in-a-product-valuation-nasdaq-imvt
0 · Reply
anachartanalyst
anachartanalyst May. 26 at 2:01 PM
$IMVT https://anachart.com/wp-content/uploads/2026/05/1779804088_soc-img.jpg
0 · Reply
ShadowBanningIsBad
ShadowBanningIsBad May. 22 at 4:32 PM
$MS $DDOG $IMVT $NXPI $VLO Remember sell high buy low.
1 · Reply
Clev21
Clev21 May. 21 at 7:24 PM
$IMVT she’s consolidating right now. Big move coming after hours
0 · Reply
KenCowboys
KenCowboys May. 21 at 2:59 PM
$IMVT trimmed just a little yesterday at $34 but will def add some back if it drops further
0 · Reply
secondideas
secondideas May. 21 at 2:51 PM
$IMVT dilution offering
0 · Reply
Quantumup
Quantumup May. 21 at 2:25 PM
TD Cowen⬆️ $ROIV's PT to $41 and reiterated at Buy. $IMVT $ABUS TD Cowen said—IMVT-1402 Shines In D2T RA, Many More Catalysts On Deck IMVT-1402 toplined impressive Ph2b D2T RA data w/ACR20 of 73%, ACR50 of 55%, and ACR70 of 36%. Brepo in CS received FDA BTD, on track to initiate Ph3 in H2:26. Brepo DM launch in late Sept, with our KOL anticipating bolus at launch. Next catalysts: brepo Ph3 data in NIU & mosli Ph2b data in PH-ILD in H2:26. Commercial launch of IMVT-1402 in Graves' & D2T RA expected in '27/28. New PT $41 (+$3).
2 · Reply
GlobalMarketBulletin
GlobalMarketBulletin May. 21 at 10:46 AM
$IMVT Immunovant Inc. (NASDAQ: IMVT) exploded more than 35% after strong IMVT-1402 rheumatoid arthritis trial results excited biotech investors. With bullish analyst support and more updates expected in 2026, IMVT suddenly became one of the hottest healthcare stocks to watch. https://globalmarketbulletin.com/can-immunovant-imvt-turn-its-rheumatoid-arthritis-trial-win-into-a-bigger-fda-story/
0 · Reply
Quantumup
Quantumup May. 21 at 10:33 AM
BofA⬆️ $IMVT's PT to $43 and reiterated at Buy $ROIV $ARGX JNJ LLY - INCY ABBV UCBJY AZN BofA said: We raise our Immunovant (IMVT) PO to $43/sh (from $32) on a higher peak sales outlook for IMVT-1402, now $6.8BN (vs. $5.5BN prior), driven by greater contribution from GD & D2T RA-both large 'white-space' TAMs. Our revision incorporates DT2A derisking from Period 1 data (reported yesterday) and potential upside from upcoming pivotal readouts. We are most bullish on GD (50% of valuation) given strong prior data and unmet need. While CLE/SJD are sizable markets, we assign lower value due to higher clinical/competitive risk. We also reduce 1402 peak sales in FcRn-entrenched markets (MG, CIDP). See Exhibit 1 for updated risk-adjusted SOTP DCF. We reiterate Buy as in our view 1402's opportunity remains underappreciated.
0 · Reply
GlobalMarketBulletin
GlobalMarketBulletin May. 21 at 10:06 AM
$ALAB $IMVT $NVTS $XNDU $TE Wall Street’s latest rally created some huge winners, and these 5 stocks stood out with powerful gains, heavy trading activity, and company-specific catalysts investors are watching closely. https://globalmarketbulletin.com/top-5-stocks-delivering-big-time-gains-today/
0 · Reply
d_risk
d_risk May. 21 at 9:42 AM
$IMVT - Immunovant Inc - 10K - Updated Risk Factors 🚨 Peer Alert: Risk-factor words are +51.5% above peer average (42,389 vs 27,983 across 639 peers). IMVT flags heightened risk from non-predictive early data, fierce IMVT‑1402 competition across MG/SjD/GD/CIDP, heavy build‑out or reliance on third‑party commercialization, expanding anti-kickback/FCA and pricing regulation, and new BIOSECURE Act CMO restrictions that could disrupt its supply chain. #Biopharmaceuticals #AutoimmuneDiseases #RegulatoryRisk #CompetitivePressure #SupplyChainDisruption 🟢 Added 🟠 Removed https://d-risk.ai/IMVT/10-K/2026-05-20
0 · Reply
RunnerSignals
RunnerSignals May. 21 at 3:48 AM
stock IQ surge (May 20) $IMVT IQ score 3.32 to 4.82 arthritis trial data. 35% on 12x volume $URBN IQ score 1.81 to 5.00 record q1 earnings beat. cleanest setup $KURA IQ score confirmed 5.00 second session. uptrend intact full breakdown https://stocksrunner.com/news/2026-05-20-stock-iq-surge-top-signal-movers
0 · Reply
Spicy_Trade
Spicy_Trade May. 20 at 11:37 PM
Immunovant, Inc. ( $IMVT )SpicyTrade - Daily Stock Analysis https://youtu.be/5ceIfCJ3E7Y?si=I0c0WA25PtZ_1nS-
0 · Reply
Doozio
Doozio May. 20 at 11:36 PM
$IMVT imagine getting MNDY 🐑 d. Bums.
0 · Reply
topstockalerts
topstockalerts May. 20 at 9:24 PM
Top Gainers PT2 $MTVA $MWC $PETZ $MLGO $IMVT
0 · Reply
topstockalerts
topstockalerts May. 20 at 9:21 PM
$IMVT something about this tape feels very controlled.
0 · Reply
FibonacciTrader_
FibonacciTrader_ May. 20 at 9:12 PM
Tech, finance, energy, and semis all showing serious strength today — these names touched fresh 52-week highs: $MS – Banking heavyweight, market confidence showing $DDOG – Cloud monitoring king, growth story intact $IMVT – Biotech momentum surging, watch for catalysts $NXPI – Semiconductor exposure firing on all cylinders $VLO – Energy rally fueled by tight crude + refinery margins Market breadth is wide, but runs like this can shake weak hands fast. Are you going to miss out again?
0 · Reply
mikesterz7
mikesterz7 May. 20 at 8:52 PM
$IMVT Immunovant posted encouraging Phase 2 data for its rheumatoid arthritis therapy, even as fourth-quarter net loss came in wider than expected.
1 · Reply